EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

TERT promoter mutations in papillary thyroid carcinoma: association with gross extrathyroidal invasion and outcomes

Debora L S Danilovic iD, Livia Elias, Ibere Soares, Giovana Torrezan, Mariana Souza, Rosalinda Camargo, Ana O Hoff, Suemi Marui, Luiz Kowalski, Peter Kopp

European Thyroid Journal · 2026

DOI: 10.1530/etj-26-0128 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Thyroid Journal, 2026. Verfasst von Debora L S Danilovic und 9 weiteren Autor:innen. Beteiligte Einrichtung: Laboratorio de Endocrinologia Celular e Molecular (LIM25), Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo , Sao Paul…. Hauptthemen laut MEDLINE: Thyroid Neoplasms, Telomerase, Mutation, Promoter Regions, Genetic. Die Arbeit nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Context

Morbidity of papillary thyroid carcinoma (PTC) is primarily related to locoregional and distant metastases. Extrathyroidal extension (ETE) is associated with adverse outcomes; however, the biological heterogeneity across its degrees – particularly minimal (mETE) versus gross ETE (gETE) – remains incompletely characterized. While BRAFV600E and TERT promoter (TERTp) mutations have been linked to aggressive disease, their contributions to ETE severity are not fully established.

Objective

This study aimed to compare clinical outcomes across different degrees of ETE and evaluate the association between molecular alterations and local aggressiveness in PTC.

Methods

A total of 352 PTCs (242 mETE; 81 gETE-T3; 29 gETE-T4) were evaluated for lymph node and distant metastases, disease recurrence/persistence, and response to therapy. BRAFV600E and TERTp (C228T/C250T) mutations were analyzed in 68 mETE and 28 gETE tumors and correlated with clinical outcomes.

Results

Increasing ETE severity was associated with progressively higher risks of lymph node and distant metastases, recurrence/persistence, and incomplete response to therapy (all P < 0.001), independent of other risk factors. BRAFV600E prevalence did not differ between tumors with mETE (82.4%) and gETE (71.4%). In contrast, TERTp mutations were more frequent in gETE (46.4%) than mETE (16.2%; P = 0.002) and were independently associated with gETE, distant metastases, and incomplete response to therapy.

Conclusion

Gross ETE is associated with progressively worse clinical outcomes, particularly in gETE-T4 tumors. While BRAFV600E does not distinguish microscopic from macroscopic invasion, TERTp mutations are associated with invasive local behavior, distant metastases, and incomplete response to therapy. These findings suggest that TERTp status may refine risk stratification in PTC with extrathyroidal extension.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Thyroid NeoplasmsTelomeraseMutationPromoter Regions, GeneticThyroid Cancer, PapillaryHumansProto-Oncogene Proteins B-rafNeoplasm InvasivenessFemaleMaleMiddle AgedAdultCarcinoma, PapillaryLymphatic MetastasisAgedNeoplasm Recurrence, Local

Stichwörter der Autor:innen

BRAF V600ETERT promoter mutationextrathyroidal extensionlocal invasionpapillary thyroid carcinomarisk stratification

Substanzen

TelomeraseProto-Oncogene Proteins B-rafTERT protein, humanBRAF protein, human

Autor:innen und Institutionen

  • Laboratorio de Endocrinologia Celular e Molecular (LIM25), Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo , Sao Paulo, SP, Brazil.
  • Endocrinology, Instituto do Cancer do Estado de Sao Paulo, Faculdade de Medicina, Universidade de Sao Paulo , Sao Paulo, SP, Brazil.
  • Pathology, Instituto do Cancer do Estado de Sao Paulo, Faculdade de Medicina, Universidade de Sao Paulo , Sao Paulo, SP, Brazil.
  • Clinical and Functional Genomics Group, A C Camargo Cancer Center , Sao Paulo, SP, Brazil.
  • Head and Neck Surgery, Instituto do Cancer do Estado de Sao Paulo and Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo , Sao Paulo, SP, Brazil.
  • Division of Endocrinology, Diabetes and Metabolism, University of Lausanne , Lausanne, Switzerland.

ORCID-Profile: Debora L S Danilovic

Zitieren

APA

Danilovic, D. L. S., Elias, L., Soares, I., Torrezan, G., Souza, M., Camargo, R., Hoff, A. O., Marui, S., Kowalski, L., & Kopp, P. (2026). TERT promoter mutations in papillary thyroid carcinoma: association with gross extrathyroidal invasion and outcomes. European Thyroid Journal. https://doi.org/10.1530/etj-26-0128

Vancouver

Danilovic DLS, Elias L, Soares I, Torrezan G, Souza M, Camargo R, et al. TERT promoter mutations in papillary thyroid carcinoma: association with gross extrathyroidal invasion and outcomes. European Thyroid Journal. 2026. doi:10.1530/etj-26-0128

BibTeX
@article{Danilovic2026,
  author = {Danilovic, Debora L S and Elias, Livia and Soares, Ibere and Torrezan, Giovana and Souza, Mariana and Camargo, Rosalinda and Hoff, Ana O and Marui, Suemi and Kowalski, Luiz and Kopp, Peter},
  title = {TERT promoter mutations in papillary thyroid carcinoma: association with gross extrathyroidal invasion and outcomes},
  journal = {European Thyroid Journal},
  year = {2026},
  doi = {10.1530/etj-26-0128}
}
Kostenlos starten →